The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration. Clinical Trial
Official title:
The Significances of Atropin Administration for the GLP-1 Potentiation of Glucose Induced Insulin Secretion and the Cephalic Insulin Response
The aim of this study is to investigate the role of transmission of vagal cholinerg for the
GLP-1 potentiation of the glucose stimulated insulin secretion and the cephalic insulin
response by using atropin administration.
The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous
system and for this reason the investigators will research individuals with an intact
nervous supply with and without atropin administration.
| Status | Recruiting |
| Enrollment | 10 |
| Est. completion date | December 2012 |
| Est. primary completion date | December 2012 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Male |
| Age group | 18 Years to 45 Years |
| Eligibility |
Inclusion Criteria: - age between 18 and 45 years - normal fasting plasma glucose - normal hemoglobin - informed consent Exclusion Criteria: - diabetes mellitus - body mass index above 30 - inflamatoric bowel disease - intestinal surgery - serum creatinine above 250 microM - ALAT above to times normal value - treatment with medicine wich cannot be paused for 12 hours - contraindication for treatment with atropin |
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Diabetes research Division, Department of Internal Medicin, Gentofte Hospital | Hellerup | |
| Denmark | Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, Copenhagen Denmark | Hellerup |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Gentofte, Copenhagen | University of Copenhagen |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | insulin secretion | The insulin secretion during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration is evaluated. Also the insulin secretion during lightly elevated blood glucose during a sham-feeding with and without atropin administration is evaluated. | tree hours | No |
| Secondary | Plasma PP | 20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. | 20 time points within tree hours | No |
| Secondary | Plasma glucose | 30 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. | 30 within tree hours | No |
| Secondary | Plasma GLP-1 | 20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. | 20 time points within tree hours | No |
| Secondary | Plasma GLP-1 | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 time points within tree hours | No |
| Secondary | Plasma GLP-2 | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 time points within tree hours | No |
| Secondary | Plasma GIP | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 timepoints within tree hours | No |
| Secondary | Plasma glucagon | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 timepoints within tree hours | No |
| Secondary | Plasma glucose | 33 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 33 timepoints within tree hours | No |